Physician profile
Henry Le
NPI 1417334426
$5,136.32
in general payments reported to CMS, 2019-2025
37 companies · $910 in 2025
The $910 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,483 · 2020: $56.32 · 2021: $326 · 2022: $563 · 2023: $1,016 · 2024: $782 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,609 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,609.13 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $822.91 | 2019-2025 | |
| Lilly USA, LLC | $638.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $424.07 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $339.21 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $321.05 | 2020-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.91 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $280.11 | 2019-2025 | |
| Abbott Laboratories | $251.64 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $218.10 | 2019-2025 | Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $198.86 | 2019-2023 | Trintellix |
| Dexcom, INC. | $183.86 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $140.19 | 2019 | |
| Sanofi-Aventis U.S. LLC | $117.13 | 2019-2023 | |
| Amarin Pharma, INC. | $103.31 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $103.09 | 2019-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.